NASDAQ:PLXP

PLx Pharma - PLXP Stock Forecast, Price & News

$0.60

+0.03 (+6.12%)

(As of 10/6/2022 11:38 AM ET)

Add

Compare

Today's Range: $0.60
▼
$0.60
50-Day Range: $0.48
▼
$2.59
52-Week Range: $0.46
▼
$19.83

Volume: 486 shs
Average Volume: 288,486 shs
Market Capitalization: $17.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.50

PLx Pharma MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 2,818.3% Upside
$16.50 Price Target
Short Interest: Healthy
2.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.04) to ($1.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

461st out of 1,072 stocks

Pharmaceutical Preparations Industry

207th out of 534 stocks

3.2

Analyst's Opinion

Consensus Rating
PLx Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.50, PLx Pharma has a forecasted upside of 2,818.3% from its current price of $0.57.
Amount of Analyst Coverage
PLx Pharma has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.34% of the outstanding shares of PLx Pharma have been sold short.
Short Interest Ratio / Days to Cover
PLx Pharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in PLx Pharma has recently decreased by 33.75%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
PLx Pharma does not currently pay a dividend.
Dividend Growth
PLx Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PLXP.

0.0

News and Social Media Coverage

Search Interest
Only 6 people have searched for PLXP on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added PLx Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PLx Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.95% of the stock of PLx Pharma is held by insiders.
Percentage Held by Institutions
Only 27.73% of the stock of PLx Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for PLx Pharma are expected to grow in the coming year, from ($2.04) to ($1.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PLx Pharma is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PLx Pharma is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PLx Pharma has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About PLx Pharma (NASDAQ:PLXP) Stock

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLXP Stock News Headlines

September 12, 2022 | finance.yahoo.com

Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels

September 5, 2022 | finance.yahoo.com

PLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52k

October 6, 2022 | Investing Trends (Ad)

"The Most Critical Metal for Global Economies"

The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year.

August 20, 2022 | finance.yahoo.com

PLXP Aug 2022 5.000 call

August 15, 2022 | seekingalpha.com

PLx Pharma downgraded at Oppenheimer after Q2 miss

August 12, 2022 | marketwatch.com

PLx Pharma to Explore Strategic Alternatives, Reduces Team

August 12, 2022 | apnews.com

Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg

August 12, 2022 | markets.businessinsider.com

PLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%

October 6, 2022 | Investing Trends (Ad)

"The Most Critical Metal for Global Economies"

August 3, 2022 | nasdaq.com

Shareholders in PLx Pharma (NASDAQ:PLXP) have lost 88%, as stock drops 13% this past week

July 27, 2022 | finance.yahoo.com

PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update

July 26, 2022 | finance.yahoo.com

PLx Pharma (NASDAQ:PLXP) shareholders have endured a 89% loss from investing in the stock a year ago

June 2, 2022 | benzinga.com

JMP Securities 2022 Life Sciences Conference

June 1, 2022 | finance.yahoo.com

PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022

May 20, 2022 | finance.yahoo.com

PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

May 13, 2022 | finance.yahoo.com

PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates

May 13, 2022 | benzinga.com

A Preview Of PLx Pharma's Earnings

May 4, 2022 | finance.yahoo.com

We're Keeping An Eye On PLx Pharma's (NASDAQ:PLXP) Cash Burn Rate

May 3, 2022 | seekingalpha.com

PLXP PLx Pharma Inc.

April 22, 2022 | finance.yahoo.com

PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update

March 21, 2022 | finance.yahoo.com

The CFO and Head of Manufacturing & Supply Chain of PLx Pharma Inc. (NASDAQ:PLXP), Rita O'Connor, Just Bought 106% More Shares

March 16, 2022 | benzinga.com

Looking Into PLx Pharma's Return On Capital Employed

March 14, 2022 | benzinga.com

Raymond James Maintains Outperform on PLx Pharma, Lowers Price Target to $12

March 11, 2022 | benzinga.com

PLx Pharma: Q4 Earnings Insights

March 11, 2022 | finance.yahoo.com

PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

March 10, 2022 | benzinga.com

PLx Pharma's Earnings Outlook

March 1, 2022 | finance.yahoo.com

PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLXP Company Calendar

Last Earnings: 8/12/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/11/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PLXP
CUSIP: N/A
CIK: 1497504
Web: www.plxpharma.com
Phone: (973) 409-6541
Fax: 713-842-3052
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.50
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +2,650.0%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,130,000.00
Net Margins: -377.98%
Pretax Margin: -377.98%
Return on Equity: -205.59%
Return on Assets: -82.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.57
Quick Ratio: 4.15

Sales & Book Value

Annual Sales: $8.21 million
Price / Sales: 2.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.30 per share
Price / Book: 0.46

Miscellaneous

Outstanding Shares: 29,140,000
Free Float: 26,530,000
Market Cap: $17.48 million
Optionable: Not Optionable
Beta: 3.89

Key Executives

Mr. Michael J. Valentino (Age 68)
Exec. Chairman
Comp: $393.75k

Ms. Natasha Giordano (Age 62)
CEO, Pres & Director
Comp: $884.88k

Ms. Rita M. O'Connor CPA (Age 54)
CPA, CFO and Head of Manufacturing & Supply Chain
Comp: $623.23k

Mr. Ronald R. Zimmerman (Age 69)
Founder & Sr. Advisor

Mr. Tom Long
VP of Manufacturing & Technical Operations

Ms. Janet M. Barth
VP of Investor Relations & Corp. Communications

Ms. Joanne Cotignola
VP of Marketing

Mr. Patrick M. Lonergan (Age 87)
Member of Chief Exec. Officer Advisory Group

Mr. Charles Edmund Sheedy C.F.A. (Age 75)
CFA, Member of Chief Exec. Officer Advisory Group

Mr. Harris Kaplan M.B.A. (Age 70)
MBA, Member of Chief Exec. Officer Advisory Group

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PLXP Stock - Frequently Asked Questions

Should I buy or sell PLx Pharma stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PLXP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLXP, but not buy additional shares or sell existing shares.
View PLXP analyst ratings or view top-rated stocks.
What is PLx Pharma's stock price forecast for 2022?: 3 Wall Street analysts have issued 12 month price targets for PLx Pharma's shares. Their PLXP share price forecasts range from $12.00 to $21.00. On average, they expect the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 2,818.3% from the stock's current price.
View analysts price targets for PLXP or view top-rated stocks among Wall Street analysts.
How have PLXP shares performed in 2022?: PLx Pharma's stock was trading at $8.01 at the beginning of 2022. Since then, PLXP stock has decreased by 92.9% and is now trading at $0.5654.
View the best growth stocks for 2022 here.
When is PLx Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our PLXP earnings forecast.
How were PLx Pharma's earnings last quarter?: PLx Pharma Inc. (NASDAQ:PLXP) released its earnings results on Friday, August, 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.04. The biotechnology company earned $0.48 million during the quarter, compared to analysts' expectations of $3.65 million. PLx Pharma had a negative trailing twelve-month return on equity of 205.59% and a negative net margin of 377.98%.

What other stocks do shareholders of PLx Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX).
When did PLx Pharma IPO?: (PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.
What is PLx Pharma's stock symbol?: PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."
How do I buy shares of PLx Pharma?: Shares of PLXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PLx Pharma's stock price today?: One share of PLXP stock can currently be purchased for approximately $0.57.
How much money does PLx Pharma make?: PLx Pharma (NASDAQ:PLXP) has a market capitalization of $16.48 million and generates $8.21 million in revenue each year. The biotechnology company earns $-46,130,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.
How can I contact PLx Pharma?: PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The official website for the company is www.plxpharma.com. The biotechnology company can be reached via phone at (973) 409-6541, via email at lwilson@insitecony.com, or via fax at 713-842-3052.

This page (NASDAQ:PLXP) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PLx Pharma - PLXP Stock Forecast, Price & News

PLx Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month